Skip to main content

Table 3 Age-adjusted risk ratios (RRs) and 95% confidence intervals (CIs) of incident benign prostatic hyperplasia (BPH)-related outcomes and nocturia by body mass index (BMI) across the life-course; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

From: Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia

 

 < 25

25–29

 ≥ 30

Per 5 kg/m2 increase

p-trenda

RR

95% CI

RR

95% CI

RR

95% CI

RR

95% CI

Baseline BMI

         

Nocturiab

1.00

Referent

1.07

0.96, 1.18

1.25

1.11, 1.40

1.11

1.06, 1.16

 < 0.0001

No. of cases

363

763

389

   

Physician Diagnosisb

1.00

Referent

1.00

0.90, 1.11

0.95

0.84, 1.07

0.97

0.92, 1.02

0.26

No. of cases

377

748

321

   

Finasterideb

1.00

Referent

1.07

0.71, 1.61

1.44

0.91, 2.27

1.17

0.96, 1.42

0.11

No. of cases

32

67

40

   

Prostate volume ≥ 30 ccc

1.00

Referent

1.13

1.07, 1.21

1.10

1.02, 1.19

1.04

1.01, 1.07

0.017

No. of cases

604

1351

544

   

Elevated PSAd

1.00

Referent

0.89

0.80, 0.99

0.75

0.65, 0.85

0.86

0.81, 0.92

 < 0.0001

No. of cases

381

682

259

   

BMI at age 20

      

Nocturiab

1.00

Referent

1.09

0.99, 1.20

1.20

0.93, 1.55

1.08

1.01, 1.16

0.026

No. of cases

1124

353

38

   

Physician diagnosisb

1.00

Referent

0.98

0.88, 1.09

0.88

0.64, 1.22

0.98

0.91, 1.05

0.57

No. of cases

1098

320

28

   

Finasterideb

1.00

Referent

1.18

0.81, 1.71

e

 

1.09

0.86, 1.39

0.49

No. of cases

103

35

    

Prostate volume ≥ 30 ccc

1.00

Referent

1.05

0.99, 1.11

1.21

1.05, 1.39

1.07

1.03, 1.12

0.0006

No. of cases

1871

566

62

   

Elevated PSAd

1.00

Referent

0.98

0.88, 1.10

0.70

0.47, 1.04

0.93

0.86, 1.01

0.074

No. of cases

1006

296

20

   

BMI at age 50

      

Nocturiab

1.00

Referent

1.07

0.98, 1.18

1.18

1.04, 1.34

1.09

1.03, 1.15

0.0021

No. of cases

480

794

241

   

Physician diagnosisb

1.00

Referent

0.92

0.84, 1.01

0.92

0.80, 1.05

0.95

0.93, 1.01

0.13

No. of cases

504

730

212

   

Finasterideb

1.00

Referent

1.07

0.73, 1.57

1.49

0.93, 2.41

1.18

0.96, 1.46

0.12

No. of cases

42

70

27

   

Prostate volume ≥ 30 ccc

1.00

Referent

1.08

1.02, 1.15

1.11

1.02, 1.20

1.05

1.02, 1.09

0.0048

No. of cases

796

1341

362

   

Elevated PSAd

1.00

Referent

0.91

0.82, 1.00

0.75

0.64, 0.89

0.85

0.79, 0.90

 < 0.0001

No. of cases

476

682

164

   
  1. BPH: benign prostatic hyperplasia; CI: Confidence Interval; BMI: body mass index; RR: risk ratio
  2. aFor continuous BMI
  3. bAlso adjusted for time between completion of the baseline and supplemental questionnaires
  4. cAlso adjusted for number of DREs and time between participants’ first and last DRE
  5. dAlso adjusted for number of PSA tests and time between participants’ first and last PSA test
  6. eToo few cases (n = 1) to estimate